You are viewing the site in preview mode
Skip to main content
| |
Model 1
|
Model 2
|
Model 3
|
Model 4
|
|---|
|
Right baPWV
| | | |
|
Week 52
|
− 78.3 (− 173.1, 16.6)
|
− 87.1 (− 186.0, 11.9)
|
− 90.9 (− 189.9, 8.1)
|
− 84.6 (− 180.6, 11.4)
|
|
Week 104
|
− 126.5 (− 211.0, − 42.0)#
|
− 136.9 (− 226.5, − 47.2)#
|
− 140.5 (− 230.2, − 50.7)#
|
− 134.4 (− 221.3, − 47.4)#
|
|
Left baPWV
| | |
|
Week 52
|
− 77.2 (− 171.0, 16.7)
|
− 92.2 (− 190.0, 5.6)
|
− 94.6 (− 192.7, 3.4)
|
− 82.2 (− 178.3, 14.0)
|
|
Week 104
|
− 115.6 (− 196.3, − 34.9)#
|
− 132.8 (− 219.3, –46.3)#
|
− 134.6 (− 221.4, –47.8)#
|
− 121.4 (− 205.7, − 37.2)#
|
|
Mean baPWV
| | |
|
Week 52
|
− 77.9 (− 170.1, 14.2)
|
− 89.7 (− 185.8, 6.4)
|
− 93.0 (− 189.2, 3.3)
|
− 83.6 (− 177.6, 10.3)
|
|
Week 104
|
− 121.1 (− 200.5, − 41.6)#
|
− 134.7 (− 219.3, –50.0)#
|
− 137.6 (− 222.5, − 52.7)#
|
− 128.0 (− 210.3, − 45.6)#
|
- Treatment effect (tofogliflozin–conventional treatment) is expressed as mean change (95% CI). Differences in delta change in baPWV from the baseline at weeks 52 and 104 between the groups at each point (treatment effect) were analyzed with a mixed-effects model for repeated measures. *p < 0.05, #p < 0.01, §p < 0.001. Model 1: treatment group, week, interactions between treatment groups and week, body mass index, HbA1c, total cholesterol, high-density lipoprotein cholesterol, triglyceride, and systolic blood pressure were included as fixed effects. Model 2: Model 1 plus smoking, DPP-4 inhibitors, pioglitazone, angiotensin-converting enzyme/angiotensin II receptor blocker, statins, and anti-platelets were included as fixed effects. Model 3: Model 1 plus smoking, hypoglycemic agents, angiotensin-converting enzyme/angiotensin II receptor blocker, statins, and anti-platelets were included as fixed effects. Model 4: Model 1 plus hypertension, smoking, hypoglycemic agents, antihypertensive agents, statins, and anti-platelets were included as fixed effects
